In addition, the immunohistochemical analysis showed that the expression of CEACAM6 was significantly decreased in high‐dose of 131I‐tinurilimab treatment mice compared with mice treated with free 131I (Figure 6D), which suggesting that the gradual escalation of 131I‐tinurilimab uptake by tumors was ascribable to its specific targeting and immunoreactivity, which ultimately accumulate in the tumor to eliminate cells, thereby reducing the expression of CEACAM6. Here, CEACAM6 is linked to neoplasm.